A Case of JAK2V617F-Negative Myeloproliferative Neoplasm in a Young Female Presenting With Extreme Thrombocytosis

被引:0
|
作者
Kumar, Kelash [1 ]
Koubeissy, Assile [1 ]
Pulenthiran, Arichanah [1 ]
Kumar, Amrat [2 ]
Gulati, Amit [1 ]
Wolf, Brian [3 ]
Peeke, Stephen [3 ]
机构
[1] Maimonides Hosp, Dept Internal Med, Brooklyn, NY 11219 USA
[2] Bassett Med Ctr, Dept Internal Med, Cooperstown, NY USA
[3] Maimonides Hosp, Dept Hematol & Oncol, Brooklyn, NY 11219 USA
关键词
hydroxyurea use; splenomegaly; jak inhibitor; extreme thrombocytosis; chronic myeloid leukemia (cml); CHRONIC MYELOID-LEUKEMIA;
D O I
10.7759/cureus.50679
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombocytosis is a commonly observed condition in clinical practice and typically results from various pathophysiological factors, such as iron deficiency, blood loss, infection, medications, rheumatologic conditions, malignancy, asplenia, post-splenectomy, or familial factors. However, extreme thrombocytosis, defined as a platelet count > 10,000 K/UL (equal or greater than a million), is a rare occurrence. In this report, we present a compelling case of severe thrombocytosis attributed to underlying chronic myelogenous leukemia (CML), further complicated by coexisting iron deficiency. It is essential to emphasize that not all instances of extreme thrombocytosis are indicative of essential thrombocythemia. Hence, maintaining a high level of suspicion for non-ET myeloproliferative neoplasms (MPNs) such as CML, as well as other underlying conditions like iron deficiency anemia, is crucial for accurate diagnosis and timely management.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients
    C M Butcher
    U Hahn
    L B To
    J Gecz
    E J Wilkins
    H S Scott
    P G Bardy
    R J D'Andrea
    Leukemia, 2008, 22 : 870 - 873
  • [32] Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
    A Pardanani
    T L Lasho
    C Finke
    C A Hanson
    A Tefferi
    Leukemia, 2007, 21 : 1960 - 1963
  • [33] Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm
    Chen, Peisong
    Ouyang, Juan
    Liang, Jianming
    Yu, Xuegao
    Huang, Bin
    CLINICAL LABORATORY, 2016, 62 (08) : 1477 - 1481
  • [34] Comparison of JAK2 V617F positive and negative myeloproliferative diseases
    Szilvasi, A.
    Andrikovics, H.
    Meggyesi, N.
    Tamaska, J.
    Halm, G.
    Lueff, S.
    Nahajevszky, S.
    Egyed, M.
    Varkonyi, J.
    Mikala, G.
    Sipos, A.
    Tordai, A.
    Masszi, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 379 - 379
  • [35] Concomitant BCR-ABL and JAK2 V617F in a Patient with Myeloproliferative Neoplasm: A Case Report
    Suzana, Alia A.
    Azlin, I
    Hafiza, A.
    Rafeah, Nor T.
    Mariam, Siti T.
    Norunaluwar, J.
    Salwati, S.
    Azma, R. Z.
    MEDICINE AND HEALTH, 2023, 18 (01): : 233 - 240
  • [36] JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis
    Maddali, Madhavi
    Kulkarni, Uday Prakash
    Ravindra, Niveditha
    Jajodia, Ekta
    Arunachalam, Arun Kumar
    Suresh, Hemamalini
    Venkatraman, Arvind
    George, Biju
    Mathews, Vikram
    Balasubramanian, Poonkuzhali
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 983 - 989
  • [37] JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis
    Madhavi Maddali
    Uday Prakash Kulkarni
    Niveditha Ravindra
    Ekta Jajodia
    Arun Kumar Arunachalam
    Hemamalini Suresh
    Arvind Venkatraman
    Biju George
    Vikram Mathews
    Poonkuzhali Balasubramanian
    Annals of Hematology, 2020, 99 : 983 - 989
  • [38] Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
    Pardanani, A.
    Lasho, T. L.
    Finke, C.
    Hanson, C. A.
    Tefferi, A.
    LEUKEMIA, 2007, 21 (09) : 1960 - 1963
  • [39] Myeloid blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
    Theocharides, Alexandre
    Boissinot, Marjorie
    Garand, Richard
    Girodon, Francois
    Teo, Soon-Siong
    Lippert, Eric
    Tichelli, Andre
    Hermouet, Sylvie
    Skoda, Radek C.
    BLOOD, 2006, 108 (11) : 115A - 115A
  • [40] Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report
    Waiswa, Musa
    Seremba, Emmanuel
    Ocama, Ponsiana
    Ddungu, Henry
    Opio, Keneth
    Okello, Clement
    O'shea, Timothy
    Verhovsek, Madeleine
    Mutyabule, Richard
    AFRICAN HEALTH SCIENCES, 2014, 14 (04) : 1069 - 1073